Myriam Curet, who serves as Executive Vice President and Chief Medical Officer at Intuitive Surgical Inc (NASDAQ: ISRG), completed a sale of 105 shares of the company's common stock at a price of $493.95 per share, generating proceeds of $51,864.
Records filed on a Form 4 with the Securities and Exchange Commission show that Curet simultaneously exercised options to acquire 105 shares of Intuitive Surgical common stock at an exercise price of $229.39 per share, for a total cost of $24,085. Following these transactions, the filing reports Curet directly holds 0 shares of Intuitive Surgical common stock and indirectly holds 409 shares through a trust.
At the time of the filing, Intuitive Surgical is trading with a market capitalization of $174.5 billion and a price-to-earnings ratio of 62.24. Separate analysis cited in public materials characterizes the stock as appearing overvalued according to InvestingPro, even as the company continues to show solid top-line momentum with revenue growth of 20.5% as referenced by that same analysis.
Operationally, Intuitive Surgical reported a strong fourth quarter for 2025, delivering revenues of $2.87 billion, an increase of 19% year over year. That quarterly result exceeded both Stifel's projection and consensus estimates, which had been $2.72 billion.
The company has also completed the acquisition of its distribution business in Southern Europe, bringing direct operations to markets including Italy, Spain, and Portugal. The move shifts those regional distribution responsibilities onto Intuitive's own operations.
Several research firms have responded positively to the company's recent performance and strategic progress. Freedom Capital Markets upgraded the stock to Buy and pointed to the rollout of the da Vinci 5 surgical system as a favorable catalyst. TD Cowen initiated coverage with a Buy rating, while Truist Securities reiterated its Buy stance, highlighting potential upside to earnings per share and an improved gross margin outlook for 2026.
This article presents the transaction and related corporate developments as reported in regulatory filings and public research notes. Investors interested in additional proprietary insights are directed to specialized subscription products referenced by InvestingPro for more detailed ProTips and dedicated research reports.
Summary of transaction data
- Shares sold: 105
- Sale price per share: $493.95
- Proceeds from sale: $51,864
- Options exercised: 105 shares at $229.39 per share; total $24,085
- Direct holdings after transaction: 0 shares
- Indirect holdings after transaction: 409 shares by trust
The facts above are drawn from the Form 4 disclosure and published company results and research notes cited alongside the filing.